-
Mashup Score: 0JNCCN 360 - Advanced Skin Cancers - Michael K.K. Wong, PhD, MD, on Early Results on Navtemadlin, a Novel MDM2 Inhibitor, for Merkel Cell Carcinoma - 1 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Clinical Trials to Watch: December 2023 - 5 month(s) ago
Treatment of advanced melanoma has dramatically improved over the past decade with 16 new therapies approved by the Food and Drug Administration (FDA). Even with these treatment advances, 50% of patients with advanced melanoma will either not respond to any of these treatments or their disease will progress creating a…
Source: www.curemelanoma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 - 7 month(s) ago
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, are also available to patients.
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 - 7 month(s) ago
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, are also available to patients.
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Sun Protection - 8 month(s) ago
No single method of sun protection can safeguard you perfectly. A complete strategy is the best way to protect yourself against skin cancer.
Source: www.skincancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Association of a Mediterranean Lifestyle With All-Cause and Cause-Specific Mortality: A Prospective Study from the UK Biobank - 9 month(s) ago
To examine the association between the Mediterranean lifestyle and all-cause, cancer, and cardiovascular disease (CVD) mortality in a British population.
Source: www.mayoclinicproceedings.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The American Society of Breast Surgeons | ASBrS - 9 month(s) ago
Committed to continually improving the practice of breast surgery.
Source: www.breastsurgeons.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 2Intermediate-thickness melanoma: A population-based study of surgical quality metrics - PubMed - 9 month(s) ago
Despite clear guidelines, one-third of intermediate-thickness melanoma patients in a recent cohort did not have recommended lymph node surgery. Lymph node status is a key determinant of the relative benefit of adjuvant systemic therapy and the need for active surveillance of pathologically node-posi …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5American Cancer Society Updates and Resources - 9 month(s) ago
“I Love You Get Screened” campaign, Second Annual National Lung Cancer Screening Day, and more.
Source: www.facs.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 5UV Radiation - 10 month(s) ago
Understand the basics about UV radiation and how it damages your skin, learn about the UV index and how to protect against skin cancer.
Source: www.skincancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet
JNCCN 360 - Advanced Skin Cancers - Michael K.K. Wong, PhD, MD, on Early Results on Navtemadlin, a Novel MDM2 Inhibitor, for Merkel Cell Carcinoma https://t.co/6KyxEIAM9u